PHASE IB STUDY OF SELICRELUMAB (CD40 AGONIST) IN COMBINATION WITH ATEZOLIZUMAB (ANTI-PD-L1) IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：8

作者：

Barlesi, Fabrice ^{[1
]}

Lolkema, Martijn ^{[2
]}

Rohrberg, Kristoffer Staal ^{[3
]}

Hierro, Cinta ^{[4
]}

Marabelle, Aurelien ^{[5
]}

Razak, Albiruni Abdul ^{[6
]}

Teixeira, Luis ^{[7
]}

Boni, Valentina ^{[8
]}

Miller, Wilson H. ^{[9
]}

Aggarwal, Charu ^{[10
]}

Stern, Martin ^{[11
]}

Cirovic, Olivera ^{[12
]}

Romagnoli, Barbara ^{[12
]}

Christen, Randolph ^{[12
]}

Dodia, Raksha ^{[13
]}

Smart, Kevin ^{[13
]}

Reis, Bernhard ^{[12
]}

Staedler, Nicolas ^{[11
]}

Watson, Carl ^{[14
]}

Steeghs, Neeltje ^{[15
]}

机构：

[1] Gustave Roussy Canc Campus, Villejuif, France

[2] Erasmus MC Canc Inst, Rotterdam, Netherlands

[3] Rigshosp, Copenhagen, Denmark

[4] Vall dHebron Univ Hosp, Barcelona, Spain

[5] Univ Paris Saclay, Gustave Roussy, Villejuif, France

[6] Princess Margaret Canc Ctr, Toronto, ON, Canada

[7] St Louis Hosp, AP HP, Paris, France

[8] START Madrid, Madrid, Spain

[9] Jewish Gen Hosp, Montreal, PQ, Canada

[10] Univ Penn, Philadelphia, PA 19104 USA

[11] Roche Innovat Ctr Zurich, Schlieren, Switzerland

[12] Roche Innovat Ctr Basel, Basel, Switzerland

[13] Roche Innovat Ctr Welwyn, Welwyn Garden City, Herts, England

[14] A4P Consulting Ltd, Sandwich, Kent, England

[15] Netherlands Canc Inst, Amsterdam, Netherlands

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷

关键词：

D O I：

10.1136/jitc-2020-SITC2020.0291

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

291

引用

页码：A178 / A178

页数：1

共 50 条

[1] Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
Machiels, Jean-Pascal
Gomez-Roca, Carlos
Michot, Jean-Marie
Zamarin, Dmitriy
Mitchell, Tara
Catala, Gaetan
Eberst, Lauriane
Jacob, Wolfgang
Jegg, Anna-Maria
Cannarile, Michael A.
Watson, Carl
Babitzki, Galina
Korski, Konstanty
Klaman, Irina
Teixeira, Priscila
Hoves, Sabine
Ries, Carola
Meneses-Lorente, Georgina
Michielin, Francesca
Christen, Randolph
Ruttinger, Dominik
Weisser, Martin
Delord, Jean-Pierre
Cassier, Philippe
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[2] A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors
Tran, Ben
Voskoboynik, Mark
Bendell, Johanna
Gutierrez, Martin
Lemech, Charlotte
Day, Daphne
Frentzas, Sophia
Garrido-Laguna, Ignacio
Standifer, Nathan
Wang, Fujun
Ferte, Charles
Wang, Yue
Das, Mayukh
Carneiro, Benedito A.
IMMUNOTHERAPY, 2024, 16 (11) : 759 - 774
[3] Mechanisms governing efficacy of combination CD40 agonist and anti-PD-L1 in pancreatic ductal adenocarcinoma
Burrack, Adam L.
Rollins, Meagan R.
Spartz, Ellen J.
Raynor, Jackson F.
Wang, Iris
Mitchell, Jason
Kaisho, Tsuneyasu
Fife, Brian
Kedl, Ross
Shen, Stephen
Stromnes, Ingunn M.
CANCER RESEARCH, 2020, 80 (16)
[4] A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.
Infante, Jeffrey R.
Hansen, Aaron Richard
Pishvaian, Michael J.
Chow, Laura Quan Man
McArthur, Grant A.
Bauer, Todd Michael
Liu, Stephen V.
Sandhu, Shahneen Kaur
Tsai, Frank Yung -Chin
Kim, Jeong
Stefanich, Eric
Li, Chi -Chung
Gilber, Houston
Mccall, Bruce
Anderson, Maria S.
Huseni, Mahrukh
Rhee, Ina Park
Siu, Lillian L.
Gordon, Michael S.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.
Vaena, Daniel A.
Chaves, Jorge
Vogelzang, Nicholas J.
Matrana, Marc Ryan
Gabayan, A. Eli
Riese, Matthew John
Cho, Daniel C.
Tagliaferri, Mary Ann
Zalevsky, Jonathan
Xie, Sunny
Hoch, Ute
Rizwan, Ahsan Naqi
Aung, Sandra
Imperiale, Michael
Schwarz, James K.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Phase I study of anti-PD-L1 antibody MPDL3280A in patients with advanced solid tumors
Murakami, Haruyasu
Yamamoto, Noboru
Kenmotsu, Hirotsugu
Takahashi, Toshiaki
Fujiwara, Yutaka
Mizugaki, Hidenori
Ishida, Yoshimasa
Kawakami, Tomohisa
ANNALS OF ONCOLOGY, 2015, 26 : 98 - 98
[7] A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/ TGF-bRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors
Xu, R-H.
Huiyan, L.
Zhao, H.
Wei, W.
Ma, D.
Yin, X.
Ni, Y.
Wang, Y.
Zhang, Y.
Zhou, J.
Pan, H.
Niu, Z.
Zhang, J.
Ren, H.
Kang, M.
Jia, W.
Gu, S.
Liu, P.
Zhang, Z.
Wang, S.
ANNALS OF ONCOLOGY, 2023, 34 : S624 - S624
[8] A phase 1 study of IMC-001, novel anti-PD-L1 antibody, in patients with advanced solid tumors
Keam, Bhumsuk
Kim, Tae Min
Oh, Do-Youn
Ock, Chan-Young
Kang, Won Ki
Park, Yeon Hee
Lee, Jeeyun
Lee, Ji Hye
Song, Yun Jeong
Park, Young Suk
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[9] Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma
Du, Yu
Dai, Jie
Mao, Lili
Wei, Xiaoting
Bai, Xue
Chen, Ling
Lin, Jing
Chi, Zhihong
Cui, Chuanliang
Sheng, Xinan
Lian, Bin
Tang, Bixia
Wang, Xuan
Yan, Xieqiao
Li, Siming
Zhou, Li
Guo, Jun
Chen, Yu
Si, Lu
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (01) : 93 - 101
[10] PHASE 1 STUDY OF AN ANTI-CD27 AGONIST AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
Shapira-Frommer, Ronnie
van Dongen, Marloes G. J.
Dobrenkov, Konstantin
Chartash, Elliot
Liu, Fang
Li, Claire
Wnek, Richard
Patel, Manish
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A2 - A2

← 1 2 3 4 5 →